Role of oxaliplatin in the treatment of colorectal cancer

Pasquale Comella, Rossana Casaretti, Claudia Sandomenico, Antonio Avallone, Luca Franco

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Oxaliplatin is a third-generation platinum compound that has shown a definite role in the management of colorectal cancer (CRC). Oxaliplatin in combination with fluorouracil and leucovorin in the FOLFOX4 regimen represents a new standard of treatment in the adjuvant setting as well as for the metastatic disease. The combination of oxaliplatin with capecitabine in the XELOX regimen has been demonstrated to be not inferior to FOLFOX4 in metastatic patients, and it is under evaluation, with or without bevacizumab, in the post-surgical management of resected patients. FOLFOX4 and XELOX regimens represent a backbone on which to add new targeted drugs. Indeed, the combination of bevacizumab with either FOLFOX4 or XELOX significantly prolonged the progression-free survival and overall survival in comparison with FOLFOX4 or XELOX combined with placebo in metastatic CRC patients, while FOLFOX4 plus cetuximab produced a significantly greater activity than FOLFOX4 alone in metastatic CRC patients with K-RAS wild type.

Original languageEnglish
Pages (from-to)229-238
Number of pages10
JournalTherapeutics and Clinical Risk Management
Volume5
Issue number1
Publication statusPublished - 2009

Fingerprint

oxaliplatin
Colorectal Neoplasms
cancer
Platinum compounds
Platinum Compounds
third generation
Leucovorin
management
Fluorouracil
Therapeutics
Disease-Free Survival
drug
Disease
Placebos
evaluation
Pharmaceutical Preparations
Survival
XELOX

Keywords

  • Adjuvant treatment
  • Advanced disease
  • Bevacizumab
  • Cetuximab
  • Colorectal cancer
  • Fluorouracil
  • Leucovorin
  • Oxaliplatin

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Safety Research
  • Chemical Health and Safety

Cite this

Role of oxaliplatin in the treatment of colorectal cancer. / Comella, Pasquale; Casaretti, Rossana; Sandomenico, Claudia; Avallone, Antonio; Franco, Luca.

In: Therapeutics and Clinical Risk Management, Vol. 5, No. 1, 2009, p. 229-238.

Research output: Contribution to journalArticle

@article{c45cc1f37f7a4284aefc0743586e018a,
title = "Role of oxaliplatin in the treatment of colorectal cancer",
abstract = "Oxaliplatin is a third-generation platinum compound that has shown a definite role in the management of colorectal cancer (CRC). Oxaliplatin in combination with fluorouracil and leucovorin in the FOLFOX4 regimen represents a new standard of treatment in the adjuvant setting as well as for the metastatic disease. The combination of oxaliplatin with capecitabine in the XELOX regimen has been demonstrated to be not inferior to FOLFOX4 in metastatic patients, and it is under evaluation, with or without bevacizumab, in the post-surgical management of resected patients. FOLFOX4 and XELOX regimens represent a backbone on which to add new targeted drugs. Indeed, the combination of bevacizumab with either FOLFOX4 or XELOX significantly prolonged the progression-free survival and overall survival in comparison with FOLFOX4 or XELOX combined with placebo in metastatic CRC patients, while FOLFOX4 plus cetuximab produced a significantly greater activity than FOLFOX4 alone in metastatic CRC patients with K-RAS wild type.",
keywords = "Adjuvant treatment, Advanced disease, Bevacizumab, Cetuximab, Colorectal cancer, Fluorouracil, Leucovorin, Oxaliplatin",
author = "Pasquale Comella and Rossana Casaretti and Claudia Sandomenico and Antonio Avallone and Luca Franco",
year = "2009",
language = "English",
volume = "5",
pages = "229--238",
journal = "Therapeutics and Clinical Risk Management",
issn = "1176-6336",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Role of oxaliplatin in the treatment of colorectal cancer

AU - Comella, Pasquale

AU - Casaretti, Rossana

AU - Sandomenico, Claudia

AU - Avallone, Antonio

AU - Franco, Luca

PY - 2009

Y1 - 2009

N2 - Oxaliplatin is a third-generation platinum compound that has shown a definite role in the management of colorectal cancer (CRC). Oxaliplatin in combination with fluorouracil and leucovorin in the FOLFOX4 regimen represents a new standard of treatment in the adjuvant setting as well as for the metastatic disease. The combination of oxaliplatin with capecitabine in the XELOX regimen has been demonstrated to be not inferior to FOLFOX4 in metastatic patients, and it is under evaluation, with or without bevacizumab, in the post-surgical management of resected patients. FOLFOX4 and XELOX regimens represent a backbone on which to add new targeted drugs. Indeed, the combination of bevacizumab with either FOLFOX4 or XELOX significantly prolonged the progression-free survival and overall survival in comparison with FOLFOX4 or XELOX combined with placebo in metastatic CRC patients, while FOLFOX4 plus cetuximab produced a significantly greater activity than FOLFOX4 alone in metastatic CRC patients with K-RAS wild type.

AB - Oxaliplatin is a third-generation platinum compound that has shown a definite role in the management of colorectal cancer (CRC). Oxaliplatin in combination with fluorouracil and leucovorin in the FOLFOX4 regimen represents a new standard of treatment in the adjuvant setting as well as for the metastatic disease. The combination of oxaliplatin with capecitabine in the XELOX regimen has been demonstrated to be not inferior to FOLFOX4 in metastatic patients, and it is under evaluation, with or without bevacizumab, in the post-surgical management of resected patients. FOLFOX4 and XELOX regimens represent a backbone on which to add new targeted drugs. Indeed, the combination of bevacizumab with either FOLFOX4 or XELOX significantly prolonged the progression-free survival and overall survival in comparison with FOLFOX4 or XELOX combined with placebo in metastatic CRC patients, while FOLFOX4 plus cetuximab produced a significantly greater activity than FOLFOX4 alone in metastatic CRC patients with K-RAS wild type.

KW - Adjuvant treatment

KW - Advanced disease

KW - Bevacizumab

KW - Cetuximab

KW - Colorectal cancer

KW - Fluorouracil

KW - Leucovorin

KW - Oxaliplatin

UR - http://www.scopus.com/inward/record.url?scp=77949450168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949450168&partnerID=8YFLogxK

M3 - Article

C2 - 19436599

AN - SCOPUS:77949450168

VL - 5

SP - 229

EP - 238

JO - Therapeutics and Clinical Risk Management

JF - Therapeutics and Clinical Risk Management

SN - 1176-6336

IS - 1

ER -